
    
      To assess the safety of two regimens of MEDI-507 administered to stem cell and bone marrow
      allograft recipients who have at least grade II acute GVHD and who have not achieved a
      satisfactory response to at least three days of corticosteroid therapy (2 mg/kg/day of
      methylprednisolone or its equivalent).
    
  